However, considering the low anti-tumor effect of GAA and the size of the pocket of MDM2, and there is no relevant literature highlighting the anti-cancer activities of synthetic GAA derivatives on potential MDM2-p53 interaction inhibitions, we decided to simply modify the structure of GAA at the carboxyl group to improve its anti-tumor activity and reduce possible pharmacokinetic problems caused by the free carboxyl group, and investigated the effects of the different GAA amide derivatives on the MDM2-p53 pathway. The gene discussed is MDM2; the disease is neoplasm.